论文部分内容阅读
为探讨α－１ｂ型重组干扰素（干扰素）治疗慢性乙型肝炎的近、远期疗效，采用干扰素３ＭＵ治疗慢性乙型肝炎９１例，设对照组９１例，并进行随访观察。结果：治疗组ＨＢｓＡｇ、ＨＢｅＡｇ、ＨＢＶＤＮＡ及ＨＢｅＡｇ和ＨＢＶＤＮＡ双阳阴转率、丙氨酸转氨酶（ＡＬＴ）复常率分别为８．８％、７１．４％、６３％、５９．５％、９０．１％，明显优于对照组，Ｐ＜０．０５或Ｐ＜０．０１；停药随访１ａ分别为１０．９８％、７０．２％、６０．４％、５７．１％、７９．１％；随访２ａ分别为１０．９８％、４８．８％、４３．９％、３９％、６２．６％；总有效率６９．２％，优于对照组３５．２％，Ｐ＜０．０１；随访１ａ时为６２．６％，２ａ时为３５．２％。
In order to investigate the short-term and long-term curative effect of α-1b type interferon (interferon) in treatment of chronic hepatitis B, 91 cases of chronic hepatitis B were treated with interferon 3MU, and 91 cases of control group were followed up. Results: The positive rates of HBsAg, HBeAg, HBVDNA and HBeAg and HBVDNA in the treatment group were 8.8%, 71.4%, 63%, 59.5% and 90%, respectively. 1%, which was significantly better than that of the control group (P <0.05 or P <0.01). The follow-up la was 10.98%, 70.2%, 60.4%, 57.1%, 79.1 %; The follow-up 2a was 10.98%, 48.8%, 43.9%, 39%, 62.6% respectively; the total effective rate was 69.2%, which was better than 35.2% of the control group, P <0. 01; 62.6% at follow-up 1a, 35.2% at 2a.